Department of Colorectal Surgery, Worthing Hospital, Washington Suite, North Wing, Worthing, West Sussex BN11 2DH, UK.
Ir J Med Sci. 2010 Jun;179(2):165-71. doi: 10.1007/s11845-009-0382-9. Epub 2009 Jun 30.
To analyse the efficacy of short-course (SCRT) versus long-course radiotherapy/chemoradiation (LCRT) as a neoadjuvant modality for the management of lower rectal cancer (LRC).
A systematic review of the literature was undertaken. Selected trials were analysed to generate a summative outcome.
Seven trials on the efficacy of SCRT versus LCRT as a neoadjuvant modality for LRC encompassing 1,675 patients were retrieved but only 2 randomized trials on 396 patients qualified for this review. In both the fixed and random effects models, LCRT and SCRT were associated with equal overall survival, tumour recurrence, perioperative complications, sphincter preservation rate and toxicity.
SCRT and LCRT may be as effective as traditional LCRT in terms of overall survival, recurrence, perioperative complications, sphincter preservation and toxicity. Traditional neoadjuvant chemoradiation may continue to be used.
分析短程放疗/放化疗（SCRT）与长程放疗/放化疗（LCRT）作为局部进展期低位直肠癌（LRC）新辅助治疗手段的疗效。
系统地对文献进行了综述。对选定的试验进行了分析，以得出总结性结果。
检索到了 7 项关于 SCRT 与 LCRT 作为 LRC 新辅助治疗手段的疗效的试验，共纳入 1675 例患者，但只有 2 项关于 396 例患者的随机试验符合本综述的纳入标准。在固定效应模型和随机效应模型中，LCRT 和 SCRT 的总生存率、肿瘤复发率、围手术期并发症、保肛率和毒性均相当。
SCRT 和 LCRT 在总生存率、复发率、围手术期并发症、保肛率和毒性方面与传统的 LCRT 可能同样有效。传统的新辅助放化疗可能继续使用。
